Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences Track

Clinical utility of amyloid PET for differential diagnosis of dementia in a typical memory clinical population.

Lars Frings, Ralph Buchert, Tobias Bormann, Philipp Meyer and Sabine Hellwig
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 562;
Lars Frings
2Uniklinik Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Buchert
1Klinik für Nuklearmedizin Charite - Universitätsmedizin Berlin Berlin Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Bormann
3Klinik fuer Neurologie Uniklinik Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Meyer
5University of Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabine Hellwig
4Klinik fuer Psychiatrie und Psychotherapie Uniklinik Freiburg Freiburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

562

Objectives: PET permits the in vivo detection of the cerebral beta-amyloid (Aβ) pathology as a hallmark of Alzheimer’s disease (AD). Therefore, Aβ PET may improve the differential diagnosis of dementias. However, actual data from real-life clinical populations supporting this expectation is limited. The present study evaluated the added value of Aβ PET beyond the clinical diagnosis alone and FDG PET alone in a typical memory clinic population.

Methods: From our clinical registry 138 cognitively impaired patients who received [18F]FDG and [11C]PIB PET were identified. Eighty-four of these were clinically diagnosed as major cognitive disorder and included into the analysis. Baseline clinical diagnoses (time of PET) and FDG PET ratings were established in a standardized, rater-blinded procedure without and with access the Aβ PET result. Diagnoses were dichotomized into AD or non-AD dementia. The added value of Aβ PET in terms of diagnostic accuracy was evaluated. An interdisciplinary consensus diagnosis incorporating all available information over a follow-up of 2.4 ± 1.3 years after PET served as reference.

Results: With additional knowledge of the Aβ PET result, diagnostic accuracy of clinical diagnosis and FDG PET improved from 71% to 89% and from 76% to 94%, respectively (p < 0.0005, McNemar tests). Gain in diagnostic accuracy was comparable in older (> 68.4 years; 19% improvement for clinical, 23% for FDG PET ratings) and younger patients (17% improvement for clinical, 12% for FDG PET ratings). Accuracy of the combined approaches (clinical diagnosis plus Aβ PIB, FDG plus Aβ PET) was higher in younger patients (93% and 98%) than in older patients (86% and 90%).

Conclusion: Amyloid PET improves the accuracy of the differential diagnosis of dementia, irrespective of the patients’ age, which is at variance with the recommendation given by the current Appropriate Use Criteria (Johnson et al., 2013). Research Support: -

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical utility of amyloid PET for differential diagnosis of dementia in a typical memory clinical population.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Clinical utility of amyloid PET for differential diagnosis of dementia in a typical memory clinical population.
Lars Frings, Ralph Buchert, Tobias Bormann, Philipp Meyer, Sabine Hellwig
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 562;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Clinical utility of amyloid PET for differential diagnosis of dementia in a typical memory clinical population.
Lars Frings, Ralph Buchert, Tobias Bormann, Philipp Meyer, Sabine Hellwig
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 562;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences Track

  • Impact of cognitive reserve in frontotemporal dementia illustrated by FDG-PET.
  • Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with 18F-FEOBV
  • Kinetic evaluation of [18F]MOZAT PET imaging in humans.
Show more Neurosciences Track

Amyloid Imaging Goes Clinical

  • Assessing the natural history of Aß-amyloid deposition with five different amyloid tracers using the Centiloid transformation
  • Voxel-based statistical analysis of amyloid PET scans in the J-ADNI multi-center study
  • Amyloid accumulation, glucose hypometabolism, and gray matter atrophy in Down syndrome
Show more Amyloid Imaging Goes Clinical

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire